Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 2
2018 3
2019 1
2020 4
2021 1
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD. Jackson ER, et al. Among authors: grand ml. Cancer Res. 2023 May 17:OF1-OF17. doi: 10.1158/0008-5472.CAN-23-0186. Online ahead of print. Cancer Res. 2023. PMID: 37195023
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdés-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD. Jackson ER, et al. Among authors: le grand m. Cancer Res. 2023 May 5;83(14):2421-37. doi: 10.1158/0008-5472.CAN-23-0186. Online ahead of print. Cancer Res. 2023. PMID: 37145169 Free PMC article.
Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms.
Ariey-Bonnet J, Berges R, Montero MP, Mouysset B, Piris P, Muller K, Pinna G, Failes TW, Arndt GM, Morando P, Baeza-Kallee N, Colin C, Chinot O, Braguer D, Morelli X, André N, Carré M, Tabouret E, Figarella-Branger D, Le Grand M, Pasquier E. Ariey-Bonnet J, et al. Among authors: le grand m. EBioMedicine. 2023 Sep;95:104752. doi: 10.1016/j.ebiom.2023.104752. Epub 2023 Aug 10. EBioMedicine. 2023. PMID: 37572644 Free PMC article.
Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers.
Savary C, Luciana L, Huchedé P, Tourbez A, Coquet C, Broustal M, Lopez Gonzalez A, Deligne C, Diot T, Naret O, Costa M, Meynard N, Barbet V, Müller K, Tonon L, Gadot N, Degletagne C, Attignon V, Léon S, Vanbelle C, Bomane A, Rochet I, Mournetas V, Oliveira L, Rinaudo P, Bergeron C, Dutour A, Cordier-Bussat M, Roch A, Brandenberg N, El Zein S, Watson S, Orbach D, Delattre O, Dijoud F, Corradini N, Picard C, Maucort-Boulch D, Le Grand M, Pasquier E, Blay JY, Castets M, Broutier L. Savary C, et al. Among authors: le grand m. Cell Rep Med. 2023 Dec 19;4(12):101339. doi: 10.1016/j.xcrm.2023.101339. Cell Rep Med. 2023. PMID: 38118405 Free PMC article.
Poly-pharmacology of existing drugs: How to crack the code?
Mouysset B, Le Grand M, Camoin L, Pasquier E. Mouysset B, et al. Among authors: le grand m. Cancer Lett. 2024 Apr 28;588:216800. doi: 10.1016/j.canlet.2024.216800. Epub 2024 Mar 14. Cancer Lett. 2024. PMID: 38492768 Free article. Review.
Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma.
Rossi M, Talbot J, Piris P, Grand ML, Montero MP, Matteudi M, Agavnian-Couquiaud E, Appay R, Keime C, Williamson D, Buric D, Bourgarel V, Padovani L, Clifford SC, Ayrault O, Pasquier E, André N, Carré M. Rossi M, et al. Among authors: grand ml. EBioMedicine. 2022 Aug;82:104149. doi: 10.1016/j.ebiom.2022.104149. Epub 2022 Jul 8. EBioMedicine. 2022. PMID: 35816899 Free PMC article.
In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.
Ariey-Bonnet J, Carrasco K, Le Grand M, Hoffer L, Betzi S, Feracci M, Tsvetkov P, Devred F, Collette Y, Morelli X, Ballester P, Pasquier E. Ariey-Bonnet J, et al. Among authors: le grand m. Mol Oncol. 2020 Dec;14(12):3083-3099. doi: 10.1002/1878-0261.12810. Epub 2020 Oct 18. Mol Oncol. 2020. PMID: 33021050 Free PMC article.
16 results